NANOFOL has adopted a specific risk amelioration strategy to attain objectives in a step-by-step approach in order to gradually improve the concept (specificity, stability, side effects and efficacy) from lower to higher risk solutions ensuring reduced animal testing and high human safety.
NANOFOL will improve treatment of chronic inflammatory diseases by fulfilling the following objectives:
Design, development and production of nanobiodevices directly targeting effector cells.
Experimental design that will enable minimal animal experimentation.
Development of a strategy to assess potential life cycle risks ensuring safe nanobiodevice-mediated delivery.
Setting-up better citizen awareness on nanomedicinebased therapies and training activities.
In vitro cultured macrophages during phagocytosis